Literature DB >> 14501788

Presentation of exogenous whole inactivated simian immunodeficiency virus by mature dendritic cells induces CD4+ and CD8+ T-cell responses.

Ines Frank1, John J Santos, Erin Mehlhop, Loreley Villamide-Herrera, Christine Santisteban, Agegnehu Gettie, Ralf Ignatius, Jeffrey D Lifson, Melissa Pope.   

Abstract

Interactions between HIV-1 and dendritic cells (DCs) play an important role in the initial establishment and spread of infection and development of antiviral immunity. We used chemically inactivated aldrithiol-2 (AT-2) simian immunodeficiency virus (SIV) with functional envelope glycoproteins to study virus interactions with DCs and developed an in vitro system to evaluate the quality of SIV antigen (Ag) presentation by DCs to T cells. AT-2 SIV interacts authentically with T cells and DCs and thus allows assessment of natural SIV-specific responses. CD4+ and CD8+ T cells from blood or lymph nodes of SIV-infected macaques released interferon-gamma (IFN gamma) and proliferated in response to a variety of AT-2 SIV isolates. Responses did not vary significantly as a function of the quantitative envelope glycoprotein content of the virions. Presentation of Ags derived from AT-2 SIV by DCs was more potent than presentation by comparably Ag-loaded monocytes. Interestingly, SIV-pulsed mature DCs stimulated both CD4+ and CD8+ T-cell responses, whereas immature DCs primarily stimulated CD4+ T cells. Further studies using AT-2 inactivated virus may help to define better the details of the virus-DC interactions critical for infection versus induction of antiviral immune responses.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14501788     DOI: 10.1097/00126334-200309010-00002

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  21 in total

Review 1.  HIV-1 and the hijacking of dendritic cells: a tug of war.

Authors:  Marie Larsson
Journal:  Springer Semin Immunopathol       Date:  2005-01

2.  Failure of HIV-exposed CD4+ T cells to activate dendritic cells is reversed by restoration of CD40/CD154 interactions.

Authors:  Rui Zhang; Jeffrey D Lifson; Claire Chougnet
Journal:  Blood       Date:  2005-11-03       Impact factor: 22.113

3.  Dendritic Cells Enhance HIV Infection of Memory CD4(+) T Cells in Human Lymphoid Tissues.

Authors:  Angel L Reyes-Rodriguez; Morgan A Reuter; David McDonald
Journal:  AIDS Res Hum Retroviruses       Date:  2016-01-07       Impact factor: 2.205

4.  A fusion inhibitor prevents spread of immunodeficiency viruses, but not activation of virus-specific T cells, by dendritic cells.

Authors:  I Frank; H Stössel; A Gettie; S G Turville; J W Bess; J D Lifson; I Sivin; N Romani; M Robbiani
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

5.  Elimination of retroviral infectivity by N-ethylmaleimide with preservation of functional envelope glycoproteins.

Authors:  David R Morcock; James A Thomas; Tracy D Gagliardi; Robert J Gorelick; J David Roser; Elena N Chertova; Julian W Bess; David E Ott; Quentin J Sattentau; Ines Frank; Melissa Pope; Jeffrey D Lifson; Louis E Henderson; Bruce J Crise
Journal:  J Virol       Date:  2005-02       Impact factor: 5.103

6.  Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.

Authors:  Edith Jasny; Suzanne Geer; Ines Frank; Panagiotis Vagenas; Meropi Aravantinou; Andres M Salazar; Jeffrey D Lifson; Michael Piatak; Agegnehu Gettie; James L Blanchard; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2012-12-01       Impact factor: 3.731

7.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

8.  A tonsillar PolyICLC/AT-2 SIV therapeutic vaccine maintains low viremia following antiretroviral therapy cessation.

Authors:  Panagiotis Vagenas; Meropi Aravantinou; Vennansha G Williams; Edith Jasny; Michael Piatak; Jeffrey D Lifson; Andres M Salazar; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  PLoS One       Date:  2010-09-21       Impact factor: 3.240

9.  Noninfectious X4 but not R5 human immunodeficiency virus type 1 virions inhibit humoral immune responses in human lymphoid tissue ex vivo.

Authors:  Wendy Fitzgerald; Andrew W Sylwester; Jean-Charles Grivel; Jeffrey D Lifson; Leonid B Margolis
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

10.  Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.

Authors:  Jeff Fairman; Joseph Moore; Mathieu Lemieux; Koen Van Rompay; Yongzhi Geng; John Warner; Kristina Abel
Journal:  Hum Vaccin       Date:  2009-03-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.